Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 15/20 | 0.48 |
| ▸ | CNR1 | P21554 | 9/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013303 | 0.88 | ALDH1A1 (0.50) | ALDH1A1CNR2CNR1MAPK14 | |
| SCHEMBL9958104 | 0.86 | CNR2 (0.58) | ALDH1A1CNR2CNR1MAPK14 | |
| SCHEMBL2635371 | 0.82 | ALDH1A1 (0.71) | ALDH1A1CNR2CNR1MAPK14 | |
| SCHEMBL13392769 | 0.74 | CNR2 (0.55) | ALDH1A1CNR2CNR1MAPK14 | |
| SCHEMBL9891815 | 0.73 | CNR2 (0.54) | ALDH1A1CNR2CNR1MAPK14 | |
| SCHEMBL9891520 | 0.73 | CNR2 (0.60) | ALDH1A1CNR2CNR1MAPK14 | |
| SCHEMBL30486167 | 0.73 | CNR2 (0.54) | ALDH1A1CNR2CNR1MAPK14 | |
| SCHEMBL26789822 | 0.72 | ALDH1A1 (0.53) | ALDH1A1CNR2CNR1MAPK14 | |
| SCHEMBL2186110 | 0.72 | CNR2 (0.50) | ALDH1A1CNR2CNR1 | |
| SCHEMBL12566298 | 0.72 | CNR2 (0.59) | ALDH1A1CNR2CNR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | ALDH1A1 1695/4885CNR2 2975/4885CNR1 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.